Latest News and Press Releases
Want to stay updated on the latest news?
-
TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...
-
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and...
-
PharmAla announces completion of onboarding for its US distribution centre and resignation of its Chief Operating Officer.
-
PharmAla incorporates a new entity in Australia to take advantage of tax incentives, and appoints Dr. Evan Lewis to its clinical advisory board.
-
PharmAla delivers over 500 LaNeo MDMA capsules to Merhavim Psychiatric Hospital to be used in a clinical trial in exchange for IP rights to trial results
-
PharmAla releases Q3 financials showing increased customer deposit and SAP sales growth
-
Pharmala files short form prospectus
-
PharmAla makes shipment to Yale, Agrees with Multidisciplinary Association for Psychedelic Studies to publicly post Investigator's Brochure for LaNeo MDMA
-
PharmAla warns the public that it does not sell MDMA to consumers, and to be on guard for illegitimate and fake products falsely being sold online.
-
PharmAla launches its Phenesafe AI, a custom-made technology stack allowing it to easily discover new MDMA-like molecules